FRI0570 Serum kl-6 level reflects severity of interstitial lung diseaseassociated with connective tissue disease

Background Measuring severity of interstitial lung disease (ILD) usually depends on the extent or pattern of imaging findings on computed tomography (CT) and the parameters of pulmonary function test. Krebs von den Lungen 6 (KL-6) is a sialylated glycoprotein mainly expressed on the surface membrane of type II pneumocytes and bronchiolar epithelial cells. Serum level of KL-6 had been reported to be associated with presence or outcome of ILD associated with connective tissue diseases (CTD-ILD). Objectives We aimed to evaluate KL-6 as a potential biomarker reflecting severity of CTD-ILD. Methods Study population was a retrospective cohort of 549 Korean patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), inflammatory myositis (IM), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE) who had concurrent ILD or not. Serum concentration of KL-6 (U/mL) was measured by Nanopia KL-6 assay (SEKISUI MEDICAL, Tokyo), using latex enhanced immunoturbidimetric assay method. Semi-quantitative grade of ILD extent (grade 1: 0%–25%, grade 2: 26%–50%, grade 3: 51%–75%, grade 4: 76%–100%) was evaluated by CT scan. To suggest cutoff value of KL-6 level to differentiate each semiquatitative grade, receiver operating characteristic curves were drawn. Student t-test and Pearson’s coefficient (PC) were applied to evaluate the correlation of KL-6 level and severity of ILD. Results The patients with CTD-ILD (n=165) had elevated serum level of KL-6 compared to CTD without ILD (n=384) (mean ±SD, 741.0±724.3 vs 236.1±157.0 U/mL, p Conclusions Serum levels of KL-6 were increased in CTD-ILD and had good correlation with CT grade, FVC, and DLCO. Higher serum level of KL-6 may reflect severity of CTD-ILD. References [1] Ishikawa N, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3–13. [2] Fathi M, et al. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271(6):589–97. [3] Kuwana M, et al. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. J Rheumatol2016;43(10):1825–31. [4] Oguz EO, et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. Clin Rheumatol2016;35(3):663–6. Disclosure of Interest None declared